Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
 arrow  CME course
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Published comments/rapid response letters
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Clark, W. F.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Plasma Exchange When Myeloma Presents as Acute Renal Failure

A Randomized, Controlled Trial

right arrow William F. Clark, MD; A. Keith Stewart, MD; Gail A. Rock, MD; Marion Sternbach, MD; David M. Sutton, MD; Brendan J. Barrett, MD; A. Paul Heidenheim, MA; Amit X. Garg, MD; David N. Churchill, MD, the Canadian Apheresis Group

6 December 2005 | Volume 143 Issue 11 | Pages 777-784

Background: Two small, randomized trials provide conflicting evidence about the benefits of plasma exchange for patients with acute renal failure at the onset of multiple myeloma.

Objective: To assess the effect of 5 to 7 plasma exchanges on a composite outcome in patients with acute renal failure at the onset of multiple myeloma.

Design: Randomized, open, controlled trial, stratified by chemotherapy and dialysis dependence, conducted from 1998 to 2004.

Setting: Hospital plasma exchange units in 14 Canadian medical centers.

Participants: 104 patients between 18 and 81 years of age with acute renal failure at the onset of myeloma.

Intervention: Study participants were randomly assigned to conventional therapy plus 5 to 7 plasma exchanges of 50 mL per kg of body weight of 5% human serum albumin for 10 days or conventional therapy alone. Ninety-seven participants completed the 6-month follow-up.

Measurements: The primary outcome was a composite measure of death, dialysis dependence, or glomerular filtration rate less than 0.29 mL·s–2·m–2 (<30 mL/min per 1.73 m2).

Results: At enrollment, the plasma exchange and control groups were similar for dialysis dependence, chemotherapy, sex, age, hypercalcemia, serum albumin level, 24-hour urine protein level, serum creatinine level, and Durie–Salmon staging. The primary composite end point occurred in 33 of 57 (57.9%) patients in the plasma exchange group and in 27 of 39 (69.2%) patients in the control group (difference between groups, 11.3% [95% CI, –8.3% to 29.1%]; P = 0.36). One third of patients in each group died.

Limitations: The study was small, used a composite outcome, and did not use renal biopsy as an inclusion criterion. Recruiting physicians were blinded to treatment allocation but not to treatment thereafter.

Conclusions: In patients with acute renal failure at the onset of multiple myeloma, there is no conclusive evidence that 5 to 7 plasma exchanges substantially reduce a composite outcome of death, dialysis dependence, or glomerular filtration rate less than 0.29 mL·s–2·m–2 (<30 mL/min per 1.73 m2) at 6 months.


Editors' Notes
space

Context

  • Does plasma exchange benefit patients with multiple myeloma and renal failure?

Contribution

  • This 6-month randomized trial involved 104 patients with acute renal failure at the onset of myeloma. A composite outcome of death, dialysis dependence, or severely reduced kidney function occurred in 57.9% of patients given 5 to 7 plasma exchanges and in 69.2% of patients given conventional therapy (difference, 11.3% [95% CI, –8.3% to 29.1%]).

Cautions

  • Although these findings suggest no substantial benefits of plasma exchange, the wide 95% CI around the difference between groups means that large benefit or some harm is possible.

—The Editors

 

Author and Article Information
space

From University of Western Ontario, London, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; University of Ottawa, Ottawa, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; and Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

ClinicalTrials.gov identifier: NCT00120263.

Grant Support: By the Canadian Institute of Health Research, Gambro BCT, and The Kidney Foundation of Canada.

Potential Financial Conflicts of Interest: Grants received: W.F. Clark (Kidney Foundation of Canada, Canadian Institute of Health Research, Gambro BCT).

Requests for Single Reprints: William F. Clark, MD, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.

Current Author Addresses: Drs. Clark and Garg and Mr. Heidenheim: London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.

Dr. Stewart: Princess Margaret Hospital, 620 University Avenue, Toronto, Ontario M5G 2C1, Canada.

Dr. Rock: The Ottawa Hospital, 1053 Carling Avenue, Ottawa, Ontario K1Y 4E9, Canada.

Drs. Sternbach and Churchill: McMaster University, St. Joseph's Hospital, 50 Charlton East, Hamilton, Ontario L8N 1A6, Canada.

Dr. Sutton: Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5C 2G4, Canada.

Dr. Barrett: Memorial University of Newfoundland, 300 Prince Philip Drive, St. Johns, Newfoundland A1B 3V6, Canada.

Author Contributions: Conception and design: W.F. Clark, A.K. Stewart, G.A. Rock, M. Sternbach, B.J. Barrett, A.P. Heidenheim, D.N. Churchill.

Analysis and interpretation of the data: W.F. Clark, A.K. Stewart, B.J. Barrett, A.P. Heidenheim, A.X. Garg, D.N. Churchill.

Drafting of the article: W.F. Clark, A.K. Stewart, A.P. Heidenheim, D.N. Churchill.

Critical revision of the article for important intellectual content: W.F. Clark, A.K. Stewart, M. Sternbach, D.M. Sutton, B.J. Barrett, A.P. Heidenheim, A.X. Garg, D.N. Churchill.

Final approval of the article: W.F. Clark, A.K. Stewart, A.X. Garg, D.N. Churchill.

Provision of study materials or patients: W.F. Clark, G.A. Rock, M. Sternbach, D.M. Sutton, D.N. Churchill.

Statistical expertise: W.F. Clark, A.P. Heidenheim, A.X. Garg, D.N. Churchill.

Obtaining of funding: W.F. Clark, A.K. Stewart, D.N. Churchill.

Administrative, technical, or logistic support: W.F. Clark, G.A. Rock.

Collection and assembly of data: W.F. Clark, A.P. Heidenheim, D.N. Churchill.


Related articles in Annals:

Editorials
Managing Myeloma Kidney
Morie A. Gertz
Annals 2005 143: 835-837. [Full Text]  

Summaries for Patients
Plasma Exchange Treatment Is Not Effective in Treating Acute Kidney Failure Caused by Multiple Myeloma
Annals 2005 143: I-20. [Full Text]  

Letters
Plasma Exchange in Multiple Myeloma
Nelson Leung
Annals 2006 144: 455. [Full Text]  

Letters
Plasma Exchange in Multiple Myeloma
William F. Clark
Annals 2006 144: 455. [Full Text]  

Letters
Correction: Plasma Exchange When Myeloma Presents as Acute Renal Failure
William F. Clark
Annals 2007 146: 471. [Full Text]  



This article has been cited by other articles:


Home page
NDT PlusHome page
U. Bachmann, R. Schindler, M. Storr, A. Kahl, A. Joerres, and I. Sturm
Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma
NDT Plus, April 1, 2008; 1(2): 106 - 108.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. X. Garg, T. Greene, and N. W. Levin
A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. Goldfarb
Update in Nephrology
Ann Intern Med, January 1, 2008; 148(1): 49 - 54.
[Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. Movilli, J. Guido, T. Silvia, S. Francesco, and C. Giovanni
Plasma exchange in the treatment of acute renal failure of myeloma
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1270 - 1271.
[Full Text] [PDF]


Home page
haematolHome page
E. Kastritis, A. Anagnostopoulos, M. Roussou, D. Gika, C. Matsouka, D. Barmparousi, I. Grapsa, E. Psimenou, A. Bamias, and M. A. Dimopoulos
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
Haematologica, April 1, 2007; 92(4): 546 - 549.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
W. F. Clark
Correction: Plasma Exchange When Myeloma Presents as Acute Renal Failure
Ann Intern Med, March 20, 2007; 146(6): 471 - 471.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. A. Hutchison, P. Cockwell, S. Reid, K. Chandler, G. P. Mead, J. Harrison, J. Hattersley, N. D. Evans, M. J. Chappell, M. Cook, et al.
Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 886 - 895.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Haubitz and D. Peest
Reply
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3602 - 3602.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
C. C. Magee
Kidney biopsy in myeloma
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3601 - 3602.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. M. Korbet and M. M. Schwartz
Multiple Myeloma
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2533 - 2545.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. Arimura, M. Li, V. Batuman, W.F. Clark, A.K. Stewart, G.A. Rock, M. Sternbach, D.M. Sutton, B.J. Barrett, A.P. Heidenheim, et al.
Cast Nephropathy in Myeloma--Does PACAP38, a New Member of the Vasoactive Intestinal Peptide Family, Open a Therapeutic Window?: Potential Protective Action of Pituitary Adenylate Cyclase-Activiating Polypeptide (PACAP38) on In Vitro and In Vivo Models of Myeloma Kidney Injury. Blood 107: 661-668, 2006
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 911 - 919.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
N. Leung
Plasma exchange in multiple myeloma.
Ann Intern Med, March 21, 2006; 144(6): 455 - 455.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. A. Gertz
Managing Myeloma Kidney
Ann Intern Med, December 6, 2005; 143(11): 835 - 837.
[Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Plasma Exchange in Multiple Myeloma
Nelson Leung
Annals Online, 21 Dec 2005 [Full text]
First, Treat the Cancer
Burton J. Lee
Annals Online, 13 Jan 2006 [Full text]
Plasma Exchange in Multiple Myeloma
Murat O. Arcasoy
Annals Online, 20 Jan 2006 [Full text]
Plasma Exchange when Myeloma Presents as Acute Renal Failure.
William F. Clark
Annals Online, 24 Jan 2006 [Full text]
Free Light Chain removal in Multiple Myeloma
Colin A Hutchison, et al.
Annals Online, 23 Mar 2006 [Full text]



 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2005 by the American College of Physicians.